Lung Cancer

The Gabrail Cancer Center currently has many Clinical Trial opportunities . For more information and to see if you qualify call Carrie Smith R.N., Director of Research at 330-492-3345 x 208 or  via email CSmith@GabrailCancerCenter.com.

A PHASE 1 FIRST-IN HUMAN, MULTI-CENTER, OPEN LABEL DOSE-ESCALATION STUDY TO DETERMINE THE SAFETY, TOLERABILITY PHARMACOKINETICS AND RP2D OF ABBV-184 AS A SINGLE AGENT IN SUBJECTS WITH PREVIOUSLY TREATED CANCERS

A randomized parallel group phase III trial of OSE 2101 as 2nd line after prior platinum-based chemotherapy failure or as 3rd line after platinum-failure and checkpoint inhibitor-failure, compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuitable for radiotherapy or metastatic Non-Small-Cell Lung Cancer. (OSE2101C301)

An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Return to Clinical Trials at GCC